Benitec Biopharma Reports Promising Interim Study Results
PremiumCompany AnnouncementsBenitec Biopharma Reports Promising Interim Study Results
2M ago
Benitec Biopharma’s BB-301 shows efficacy in Phase 1b/2a study of OPMD
Premium
The Fly
Benitec Biopharma’s BB-301 shows efficacy in Phase 1b/2a study of OPMD
2M ago
Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study
Premium
Press Releases
Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study
2M ago
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
PremiumPress ReleasesBenitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
4M ago
Benitec Biopharma reports Q3 EPS ($1.64) vs. ($2.67) last year
Premium
The Fly
Benitec Biopharma reports Q3 EPS ($1.64) vs. ($2.67) last year
4M ago
Benitec Biopharma (BNTC) Q3 Earnings Cheat Sheet
Premium
Pre-Earnings
Benitec Biopharma (BNTC) Q3 Earnings Cheat Sheet
4M ago
Benitec Biopharma reports interim trial data for subject treasted with BB-301
PremiumThe FlyBenitec Biopharma reports interim trial data for subject treasted with BB-301
5M ago
Benitec Biopharma announces $40M oversubscribed private placement financing
Premium
The Fly
Benitec Biopharma announces $40M oversubscribed private placement financing
5M ago
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
Premium
Press Releases
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100